Biome Australia Reports Stellar Sales Growth in FY24

Biome Australia Limited (ASX: BIO) has achieved remarkable sales growth in the first half of FY24, reporting unaudited sales revenue of ~$6 million, up 77.7% from H1 FY23, and Q2 sales of ~$3.3 million, an 83.3% increase from Q2 FY23. Notably, the company achieved a 20.4% quarter-on-quarter growth in Q2, traditionally a seasonally weaker period.

Biome's Managing Director, Blair Norfolk, expressed delight in the results, emphasizing the quarter's strength, making it their best to date. The growth is attributed to increased same-store sales and the general development of their Activated Probiotics range. Biome Australia focuses on developing, licensing, and marketing evidence-based live biotherapeutics and complementary medicines to enhance health outcomes globally.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com